Specific urinary immune response proteins are altered in hypertensive patients developing albuminuria despite RAS suppression, suggesting potential novel therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Candidate urinary proteins may flag albuminuria risk despite RAS suppression; leaves open validation before any clinical use.
Martin‐Lorenzo et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: